Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
API
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Deoxyephedrine
2. Desoxyephedrine
3. Desoxyn
4. Hydrochloride, Methamphetamine
5. Madrine
6. Metamfetamine
7. Methamphetamine
8. Methylamphetamine
9. N Methylamphetamine
10. N-methylamphetamine
1. 51-57-0
2. Methamphetamine Hcl
3. (+)-methamphetamine Hydrochloride
4. Adipex
5. Dexoval
6. S-(+)-methamphetamine Hydrochloride
7. Methamphetaminium Chloride
8. Tonedron
9. D-methaphetamine Hydrochloride
10. Deofed
11. Isophen
12. Desoxyn
13. Methylisomyn
14. Soxysympamine
15. Chestox
16. Desepin
17. Desodex
18. Desoxyfed
19. Desoxyne
20. Dexstim
21. Doxyfed
22. Drinalfa
23. Efroxine
24. Eufodrinal
25. Gerovit
26. Madrine
27. Pervitin
28. Syndrox
29. Destim
30. Dextim
31. Dosoxy
32. Hyphet
33. Meth
34. Obedrin-la
35. Desoxo-5
36. Metamfetamine Hydrochloride
37. Norodin Hydrochloride
38. (+)-n,alpha-dimethylphenethylamine Hydrochloride
39. Methylamphetamine Hydrochloride
40. (+)methamphetamine Hydrochloride
41. Des-o-e
42. D-desoxyephedrine Hydrochloride
43. Dee Dex 10
44. Methedrine Hydrochloride
45. Methaphetaminium Chloride
46. Semoxydrine Hydrochloride
47. Dee -5
48. Methamphetamine Hydrochloride Cii
49. Chebi:35340
50. Metamphetamine Hydrochloride
51. Dee -10
52. 997f43z9cv
53. D-o-e
54. Desoxyephedrine Hydrochloride
55. (+)-methamphetamine Chloride
56. D-methamphetamine Hydrochloride
57. Nsc-169505
58. N-methylamphetamine Hydrochloride
59. Philopon
60. Benzeneethanamine, N,alpha-dimethyl-, Hydrochloride, (alphas)-
61. (+)-methylamphetamine Hydrochloride
62. Isophen (van)
63. L-methamphetamine Hydrochloride
64. (2s)-n-methyl-1-phenylpropan-2-amine;hydrochloride
65. Gerobit
66. (+)-2-methylamino-2-phenylpropane Hydrochloride
67. D-methylamphetamine Hydrochloride
68. Levmetamfetamine Hydrochloride
69. (+)-l-methamphetamine Hydrochloride
70. Einecs 200-106-9
71. Nsc 169505
72. Wq4872m3c8
73. L-desoxyephedrine Hydrochloride
74. Unii-997f43z9cv
75. Ai3-20155
76. D-n,alpha-dimethylphenethylamine Hydrochloride
77. (s)-(+)-methamphetamine Hydrochloride
78. D-n-methyl-beta-phenylisopropylamine Hydrochloride
79. Desoxyn (tn)
80. Einecs 212-552-1
81. L-methamphetamine Hcl
82. Phenethylamine, N,alpha-dimethyl-, Hydrochloride, (+)-
83. Benzeneethanamine, N,alpha-dimethyl-, Hydrochloride, (s)-
84. Methamphetamine Hydrochloride [usp:jan]
85. (+)-methamphetamine Hydrochloride Solution
86. Ncgc00247704-01
87. Dsstox_cid_28790
88. Dsstox_rid_83059
89. Dsstox_gsid_48864
90. L-n-methyl-beta-phenylisopropylamine Hydrochloride
91. Methylamfetamine Hydrochloride
92. Schembl42100
93. N,alpha-dimethylphenethylamine Hydrochloride, (-)-
94. Unii-wq4872m3c8
95. (2s)-n-methyl-1-phenylpropan-2-amine Hydrochloride
96. (+)-(s)-n,alpha-dimethylphenethylamine Hydrochloride
97. Methamphetamine Hydrogen Chloride
98. Chembl1200952
99. Dtxsid8048864
100. Phenethylamine, N,alpha-dimethyl-, Hydrochloride, (-)-
101. Phenethylamine, N,alpha-dimethyl-, Hydrochloride, (s)-(+)-
102. Tox21_112856
103. Cas-51-57-0
104. Methamphetamine Hydrochloride (jp17/usp)
105. Methamphetamine Hydrochloride [mi]
106. Metamfetamine Hydrochloride [mart.]
107. Methamphetamine Hydrochloride [jan]
108. Metamfetamine Hydrochloride [who-dd]
109. Methamphetamine Hydrochloride [vandf]
110. D02242
111. Methamphetamine Hydrochloride [orange Book]
112. Methamphetamine Hydrochloride Cii [usp-rs]
113. Methamphetamine Hydrochloride [usp Monograph]
114. Methyl-[(2s)-1-phenylpropan-2-yl]azanium;chloride
115. Q27116464
116. (+)-(s)-n,.alpha.-dimethylphenethylamine Hydrochloride
117. Benzeneethanamine, N,.alpha.-dimethyl-, Hydrochloride, (s)-
118. Benzeneethanamine, N,alpha-dimethyl-, Hydrochloride (1:1), (alphas)-
119. Methamphetamine Hydrochloride ((s)-(+)-methamphetamine Hydrochloride)
120. Methamphetamine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
121. (+)-methamphetamine Hydrochloride Solution, Analytical Standard, For Drug Analysis, 1.0 Mg/ml In Methanol
122. Methamphetamine Hydrochloride ((s)-(+)-methamphetamine Hydrochloride) 0.1 Mg/ml In Methanol (as Free Base)
123. Methamphetamine Hydrochloride ((s)-(+)-methamphetamine Hydrochloride) 1.0 Mg/ml In Methanol (as Free Base)
| Molecular Weight | 185.69 g/mol |
|---|---|
| Molecular Formula | C10H16ClN |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 3 |
| Exact Mass | 185.0971272 g/mol |
| Monoisotopic Mass | 185.0971272 g/mol |
| Topological Polar Surface Area | 12 Ų |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 95 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | DESOXYN |
| Active Ingredient | METHAMPHETAMINE HYDROCHLORIDE |
| Company | RECORDATI RARE (Application Number: N005378) |
| 2 of 2 | |
|---|---|
| Drug Name | METHAMPHETAMINE HYDROCHLORIDE |
| Active Ingredient | METHAMPHETAMINE HYDROCHLORIDE |
| Company | MAYNE PHARMA INC (Application Number: A091189); WEST-WARD PHARMS INT (Application Number: A203846) |
Dopamine Agents
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)
Central Nervous System Stimulants
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)
Dopamine Uptake Inhibitors
Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)
Adrenergic Agents
Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (See all compounds classified as Adrenergic Agents.)
Adrenergic Uptake Inhibitors
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)
Sympathomimetics
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-08-05
Pay. Date : 2022-08-03
DMF Number : 22245
Submission : 2008-12-01
Status : Active
Type : II
NDC Package Code : 49812-0183
Start Marketing Date : 2009-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16176
Submission : 2002-10-04
Status : Active
Type : II
NDC Package Code : 61960-6030
Start Marketing Date : 2000-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25573
Submission : 2011-12-08
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15159
Submission : 2000-11-27
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15465
Submission : 2001-05-31
Status : Active
Type : II




FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Methamphetamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amphetamine-Related Disorders.
Lead Product(s): Methamphetamine Hydrochloride,Etifoxine
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: National Institute on Drug Abuse
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Methamphetamine Hydrochloride,Etifoxine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Methamphetamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amphetamine-Related Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The MDMA-LSD trial, the first-ever to combine both drugs, is scheduled to start in the fourth quarter in Basel, Switzerland. Combined MDMA-LSD treatments have the potential to create next-generation psychedelic-assisted therapy paradigms.
Lead Product(s): Methamphetamine Hydrochloride,LSD
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 25, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Methamphetamine Hydrochloride,LSD
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mind Med Announces First-Ever Clinical Trial Combining MDMA and LSD
Details : The MDMA-LSD trial, the first-ever to combine both drugs, is scheduled to start in the fourth quarter in Basel, Switzerland. Combined MDMA-LSD treatments have the potential to create next-generation psychedelic-assisted therapy paradigms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 25, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
EmpathBio, a wholly-owned subsidiary of ATAI Life Sciences is developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications.
Lead Product(s): Methamphetamine Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 24, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Methamphetamine Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EmpathBio, a wholly-owned subsidiary of ATAI Life Sciences is developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 24, 2020

Details:
MindMed has committed to fund future R&D of new psychedelic therapies being pursued by the Liechti Lab with the intention to create next-gen psychedelic inspired medicines that incorporate MDMA as a component of these therapies.
Lead Product(s): Methamphetamine Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Mind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration May 27, 2020

Lead Product(s) : Methamphetamine Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Mind Medicine
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies
Details : MindMed has committed to fund future R&D of new psychedelic therapies being pursued by the Liechti Lab with the intention to create next-gen psychedelic inspired medicines that incorporate MDMA as a component of these therapies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 27, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AA
Brand Name : METHAMPHETAMINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Approval Date : 2010-04-21
Application Number : 91189
RX/OTC/DISCN : RX
RLD : No
TE Code : AA
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AA
Brand Name : DESOXYN
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Approval Date : 1982-01-01
Application Number : 5378
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : DESOXYN
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 10MG
Approval Date : 1982-01-01
Application Number : 5378
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : DESOXYN
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 5MG
Approval Date : 1982-01-01
Application Number : 5378
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : DESOXYN
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 15MG
Approval Date : 1982-01-01
Application Number : 5378
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AA
Brand Name : METHAMPHETAMINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Approval Date : 2015-11-17
Application Number : 203846
RX/OTC/DISCN : RX
RLD : No
TE Code : AA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : METHAMPHETAMINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Approval Date : 2004-02-25
Application Number : 40529
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : METHAMPEX
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 1982-01-01
Application Number : 83889
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : METHAMPHETAMINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Approval Date : 1982-01-01
Application Number : 86359
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Brand Name : METHAMPHETAMINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Approval Date : 1982-01-01
Application Number : 84931
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
88
PharmaCompass offers a list of Methamphetamine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Methamphetamine Hydrochloride manufacturer or Methamphetamine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Methamphetamine Hydrochloride manufacturer or Methamphetamine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Methamphetamine Hydrochloride API Price utilized in the formulation of products. Methamphetamine Hydrochloride API Price is not always fixed or binding as the Methamphetamine Hydrochloride Price is obtained through a variety of data sources. The Methamphetamine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pervitin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pervitin, including repackagers and relabelers. The FDA regulates Pervitin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pervitin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pervitin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pervitin supplier is an individual or a company that provides Pervitin active pharmaceutical ingredient (API) or Pervitin finished formulations upon request. The Pervitin suppliers may include Pervitin API manufacturers, exporters, distributors and traders.
click here to find a list of Pervitin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pervitin DMF (Drug Master File) is a document detailing the whole manufacturing process of Pervitin active pharmaceutical ingredient (API) in detail. Different forms of Pervitin DMFs exist exist since differing nations have different regulations, such as Pervitin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pervitin DMF submitted to regulatory agencies in the US is known as a USDMF. Pervitin USDMF includes data on Pervitin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pervitin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pervitin suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pervitin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pervitin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pervitin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pervitin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pervitin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pervitin suppliers with NDC on PharmaCompass.
Pervitin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pervitin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pervitin GMP manufacturer or Pervitin GMP API supplier for your needs.
A Pervitin CoA (Certificate of Analysis) is a formal document that attests to Pervitin's compliance with Pervitin specifications and serves as a tool for batch-level quality control.
Pervitin CoA mostly includes findings from lab analyses of a specific batch. For each Pervitin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pervitin may be tested according to a variety of international standards, such as European Pharmacopoeia (Pervitin EP), Pervitin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pervitin USP).